Panel Will Develop Guidelines for treatment of patients with Advanced Hepatocellular Carcinoma
April 25, 2019 — The American Society of Clinical Oncology recently appointed Englewood Health’s Steven T. Brower, MD, medical director of The Lefcourt Family Cancer Treatment and Wellness Center and chief of surgical oncology, and Minaxi P. Jhawer, MD, chief of hematology and oncology, to participate in a panel focused on developing guidelines for systemic therapy for patients with hepatocellular carcinoma, the most common type of liver cancer.
As members of the Expert Panel, Dr. Brower and Dr. Jhawer are tasked with drafting and executing a systematic review, and developing treatment recommendations.
ASCO selected Drs. Brower and Jhawer for the significant contributions they would be able to make in shaping guidelines to impact not only local patients, but also patients around the world. Physicians involved in the multidisciplinary care of advanced hepatocellular carcinoma (HCC) review and follow these guidelines for their care of this complex population of patients.
“Over the past six years there have been six new drugs approved for use in advanced hepatocellular carcinoma,” said Dr. Jhawer. “Up until a decade ago we had only one active drug. It’s a tremendous honor and opportunity to be involved in writing the guidelines, which will impact the way we care for this special population of HCC patients who require detailed multidisciplinary care to get the best outcomes.”
Dr. Jhawer is also a national-peer-nominated member of the ASCO Clinical Practice Guidelines Committee, a group of 30 physicians from around the world. This multi-disciplinary panel of physicians provides evidence-based recommendations for treatment of patients with cancer, and serves as a guide for doctors around the world to utilize in their daily practice and care of cancer patients.
“We are delighted to be part of the panel and formulate guidelines with the ASCO’s experts in an effort to standardize the treatment and outcome pathways for individuals at risk for HCC,” said Dr. Brower.
The panel will participate in teleconferences to discuss development and application of the guideline.